Furthermore, IHC analysis of our PCa cohort (n = 56) showed that, compared to the nontumor samples, SRD5A1 and HSD17B3 protein expression levels were significantly upregulated in patients with primary and metastatic PCa, but SHBG and HSD17B2 protein expression levels were markedly suppressed (Figure 3E). This evidence concerns the gene SRD5A1 and posterior cortical atrophy.